Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATReceivables - Other
Ratios

Lipocine (LPCN) Non-Current Receivables (2021 - 2023)

Lipocine's Non-Current Receivables history spans 3 years, with the latest figure at $3.3 million for Q2 2023.

  • For Q2 2023, Non-Current Receivables fell 19.69% year-over-year to $3.3 million; the TTM value through Jun 2023 reached $3.3 million, down 19.69%, while the annual FY2022 figure was $3.3 million, 19.69% down from the prior year.
  • Non-Current Receivables reached $3.3 million in Q2 2023 per LPCN's latest filing, roughly flat from $3.3 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $4.0 million in Q4 2021 to a low of $3.3 million in Q3 2022.
  • Average Non-Current Receivables over 3 years is $3.6 million, with a median of $3.3 million recorded in 2022.
  • The largest YoY upside for Non-Current Receivables was 19.69% in 2022 against a maximum downside of 19.69% in 2022.
  • A 3-year view of Non-Current Receivables shows it stood at $4.0 million in 2021, then fell by 19.69% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
  • Per Business Quant, the three most recent readings for LPCN's Non-Current Receivables are $3.3 million (Q2 2023), $3.3 million (Q1 2023), and $3.3 million (Q4 2022).